MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2023
Continued strong momentum and promising signs of patient benefit in the combination study with fostrox and Lenvima[®] April – JuneFinancial summary for the quarter · Net turnover amounted to SEK 2.0 (0.5) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -26.3(-21.5) million. Basic and diluted earnings per share amounted to SEK -0.47 (-0.42) and SEK -0.47 (-0.42) respectively. · Cash flow from operating activities amounted to SEK -17.9 (-17.6) million. · Cash and cash equivalents at the end of the period amounted to SEK 82.